ATNM Actinium Pharmaceuticals Inc

Price (delayed)

$5.11

Market cap

$121.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.14

Enterprise value

$49.32M

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application ...

Highlights
ATNM's revenue has surged by 135% year-on-year and by 28% since the previous quarter
ATNM's gross profit has surged by 135% year-on-year and by 28% since the previous quarter
The quick ratio has decreased by 28% YoY but it has increased by 11% from the previous quarter
ATNM's net income is down by 12% year-on-year
The equity has declined by 6% since the previous quarter and by 2.7% year-on-year

Key stats

What are the main financial stats of ATNM
Market
Shares outstanding
23.78M
Market cap
$121.54M
Enterprise value
$49.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.64
Price to sales (P/S)
77.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.74
Earnings
Revenue
$1.46M
EBIT
-$24.58M
EBITDA
-$24.05M
Free cash flow
-$21.14M
Per share
EPS
-$1.14
Free cash flow per share
-$0.95
Book value per share
$3.11
Revenue per share
$0.07
TBVPS
$3.37
Balance sheet
Total assets
$74.56M
Total liabilities
$5.73M
Debt
$197,000
Equity
$68.84M
Working capital
$68.33M
Liquidity
Debt to equity
0
Current ratio
12.94
Quick ratio
12.65
Net debt/EBITDA
3
Margins
EBITDA margin
-1,644.8%
Gross margin
100%
Net margin
-1,681.5%
Operating margin
-1,693.3%
Efficiency
Return on assets
-30.4%
Return on equity
-32.4%
Return on invested capital
N/A
Return on capital employed
-35.7%
Return on sales
-1,681.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATNM stock price

How has the Actinium Pharmaceuticals stock price performed over time
Intraday
-1.92%
1 week
-0.97%
1 month
-8.26%
1 year
-34.82%
YTD
-14.98%
QTD
0%

Financial performance

How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$1.46M
Gross profit
$1.46M
Operating income
-$24.76M
Net income
-$24.58M
Gross margin
100%
Net margin
-1,681.5%
ATNM's revenue has surged by 135% year-on-year and by 28% since the previous quarter
ATNM's gross profit has surged by 135% year-on-year and by 28% since the previous quarter
The net margin has soared by 52% YoY and by 22% from the previous quarter
Actinium Pharmaceuticals's operating margin has soared by 52% YoY and by 22% from the previous quarter

Growth

What is Actinium Pharmaceuticals's growth rate over time

Valuation

What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.64
P/S
77.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.74
The EPS has grown by 20% YoY and by 5% from the previous quarter
The price to book (P/B) is 61% lower than the 5-year quarterly average of 4.2 and 14% lower than the last 4 quarters average of 1.9
The equity has declined by 6% since the previous quarter and by 2.7% year-on-year
ATNM's revenue has surged by 135% year-on-year and by 28% since the previous quarter
ATNM's price to sales (P/S) is 42% less than its last 4 quarters average of 134.0

Efficiency

How efficient is Actinium Pharmaceuticals business performance
The ROS has soared by 52% YoY and by 22% from the previous quarter
ATNM's return on equity is up by 15% year-on-year
The company's return on assets rose by 14% YoY

Dividends

What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNM.

Financial health

How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total liabilities has increased by 31% YoY but it has decreased by 16% from the previous quarter
The quick ratio has decreased by 28% YoY but it has increased by 11% from the previous quarter
The debt is 100% less than the equity
The company's debt to equity has shrunk by 100% YoY
The debt has plunged by 69% YoY and by 36% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.